Sage Journals: Discover world-class research

Abstract

Macrophage migration inhibitory factor (MIF) is involved in various immune-mediated pathologies and regulates both innate and adaptive immune reactions, thus being related to several acute and chronic inflammatory diseases such as rheumatoid arthritis, septic shock, and atherosclerosis. Its role in acute and chronic brain pathologies, such as stroke and neurodegenerative diseases, has attracted increasing attention in recent years. In response to stimuli like hypoxia, inflammation or infection, different cell types can rapidly release MIF, including immune cells, endothelial cells, and neuron cells. Notably, clinical data from past decades also suggested a possible link between serum MIF levels and the severity of stroke and the evolving of neurodegenerative diseases. In this review, we summarize the major and recent findings focusing on the mechanisms of MIF modulating functions in brain injury and neurodegenerative diseases, which may provide important therapeutic targets meriting further investigation.

Keywords

Macrophage migration inhibitory factor inflammatory response immune reaction stroke neurodegenerative disease

Introduction

Macrophage migration inhibitory factor (MIF), a 12.5 kD protein that inhibits macrophage migration, has been primarily recognized as a product of T lymphocytes.¹ Later, rapidly growing evidence revealed that MIF can be broadly expressed in various cell types, including macrophages, smooth muscle cells, endothelial cells, and neuron cells.^2–4 The physiopathological roles of MIF have come to light subsequently. It’s an inflammatory cytokine with chemokine-like functions that is involved in several immune-mediated pathologies and is responsible for inflammatory reactions throughout the central nervous system.^5–9 The role of MIF in pathological conditions appears to be diverse with both protective and detrimental effects. For example, MIF defective animals showed decreased neuronal death and improved recovery from transient middle cerebral artery occlusion (tMCAo) in the brain,¹⁰ suggesting its detrimental role in acute cerebrovascular diseases.^11,12 However, both ischemic and hemorrhagic models could benefit from MIF overexpression by attenuating oxidative stress.^13,14 Furthermore, evidence from both clinical studies and basic research have suggested that MIF could be the biomarker to predict the outcome of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The purpose of this review is to provide an overview of the research on MIF, with a particular focus on the context of brain injury and neurodegenerative diseases.

Regulatory mechanisms of MIF expression under different pathological contexts

The MIF gene is located on human chromosome 22 (22q11.2) and 10,¹⁵ where functional polymorphisms -794 CATT 5-8 microsatellite repeat (rs5844572) and -173 G > C single nucleotide polymorphism (SNP) (rs755622) control MIF promoter activity and MIF expression.¹⁶ It is expressed at a high level in various parts of the rat brain, including the cortex, hypothalamus, and hippocampus.¹⁶ MIF’s expression can be increased in vivo following physiological and pathological stimuli like hormones, glucose, cytokines, and microbial products.¹⁷ For instance, after lipopolysaccharide (LPS) injection, both MIF mRNA and protein levels were increased and quickly released into the cerebrospinal fluid of the rat, where cytokines such as IL-1β and IL-6 could be detected.¹⁶ A similar elevation of gene expression was also found in a LPS treated marine invertebrate model.¹⁸ What’s more, Rice et al. demonstrated that angiotensin II stimulated MIF mRNA and protein production, which induced a rapid release of 50% of MIF protein within 20 minutes in the rat proximal tubular epithelial cells.¹⁹ MIF, as previously reported, can boost transcription factor nuclear factor kappa B (NF-κB) expression, which therefore has a pro-inflammatory effect, and increasing NF-κB levels triggers MIF gene transcription, creating a feedback loop. However, these effects were context dependent, since NF-κB decreased MIF expression under hypoxia conditions, then diminished the neuronal protective effect of MIF in a cerebral ischemia mouse model.¹³ Thus, the regulation of MIF expression is dependent on the different cellular background during physiological or pathological processes.

The intracellular downstream signals of MIF

The MIF homologous receptor, a cluster of differentiation 74 (CD74) was discovered in the early twentieth century.²⁰ It is a type II transmembrane protein required for MIF-induced mitogen-activated protein kinase (MAPK) cascade activation, cyclooxygenase 2 (COX2) and prostaglandin E2 (PGE2) production, as well as cell proliferation.²⁰ CD44 or C-X-C Motif containing chemokine receptor 2 (CXCR2), CXCR4, and CXCR7 are examples of co-receptors.^21,22 MIF can activate the CD74/CD44 complex via tyrosine-protein kinase (SRC) and phosphorylate downstream MAPK family signals such as ERK1/2, PI3K, and protein kinase B (PKB), also known as AKT.^20,23–25 Then, NF-κB and activator protein-1 (AP1) will be activated,²⁶ resulting in the release of pro-inflammatory cytokines like IL-6, IL-8, IL-10, and TNF-α.²⁷ Furthermore, MIF functions as a link between NF-κB and the tumor suppressor protein p53, as p53-dependent macrophage apoptosis can be inhibited by MIF, allowing the macrophage to retain its proinflammatory properties.²⁸ In addition, MIF binding to CXCR2 and CXCR4 is linked to the activation of mononuclear cell chemotaxis, whereas CXCR7 is linked to the ERK- and zeta-chain-associated protein kinase (ZAP)-70 signaling pathways, as well as B-lymphocyte migration.^21,22 When CXCR7 and CXCR4 combine to form homo- and heterodimers, they are able to bind CXCL12 with a much more affinity than CXCR4 and subsequently mediate G-protein signaling.^29,30 The significance of CXCL12/CXCR4/CXCR7 signaling in prostate cancer of obese mice has been clarified.³¹ As a result, it can be assumed that high amounts of MIF may interfere with the CXCL12-CXCR4/CXCR7 axis by competing for binding sites especially after the stroke,³² and it has been discovered that the MIF/CXCR7/AKT pathway promotes the development and metastasis of castration-resistant prostate cancer.³³

MIF upregulated the expression of toll-like receptor 4 (TLR-4) in response to LPS and Gram-negative bacteria, which was necessary for the production of proinflammatory cytokines such as TNF-α, IL-6, and IL-12.^34–36 Moreover, MIF is involved in the inflammatory response of NLR family pyrin domain containing 3 (NLRP3) inflammasome.³⁷ Macrophages and dendritic cells (DCs) produce less IL-1α, IL-1β and IL-18 when NLRP3 inhibits MIF activation.³⁸ Hypoxia-inducible factor-1 (HIF-1) increases the transcriptional expression of MIF, and the elevated MIF level prevents HIF-1 degradation by interacting with constitutive photomorphogenesis 9 (COP9) signalosome subunit 5 (CSN5), which stabilizes HIF-1 by inhibiting its prolyl-564 hydroxylation.^28,39 What’s more, MIF inhibits the anti-inflammatory and immunosuppressive effects of glucocorticoid (GC) via MAPK phosphatase.^40,41 Figure 1 concludes the MIF-mediated immune response signaling transduction.

Figure 1.

The overview of MIF-mediated cellular signaling transduction. MIF binds the ligand-binding protein CD74 and activates MAPK cascade, COX2, and PGE2. MIF activates the CD74/CD44 complex via SRC and phosphorylates downstream ERK1/2, PI3K, and protein kinase B. NF-κB and AP1 then be activated to induce the release of IL-6, IL-8, IL-10, and TNF-α, while the tumor suppressor protein p53 is inhibited by NF-κB. HIF-1 increases the expression of MIF, and the elevated MIF stabilizes HIF-1 in turn by preventing its degradation through CSN5. MIF suppresses GC immunosuppressive effects via MAPK phosphatase and upregulates TLR-4 expression in response to LPS stimuli, then induces the production of downstream proinflammatory cytokines such as TNF-α, IL-6, and IL-12. MIF: macrophage migration inhibitory factor; MAPK: mitogen-activated protein kinase; COX2: cyclooxygenases 2; PGE2: prostaglandin E2; SRC: tyrosine-protein kinase; ERK: extracellular regulated protein kinases; PI3K: Phosphoinositide 3-kinase; AP1: activator protein-1; IL: interleukin; TNF: tumor necrosis factor; HIF-1: Hypoxia-inducible factor-1; CSN5: constitutive photomorphogenesis 9 signalosome subunit 5; GC: glucocorticoid; TLR-4: toll-like receptor 4. The figure were created with BioRender.com.

Divergent pathological mechanisms of MIF in different brain resident cells

Double side effects on neuronal cells

In addition to serving as an immune mediator, MIF has a direct influence on neuronal cells. The protective effects of MIF on neuronal cells via blocking microglial activation were discovered at the end of last century.⁴² Sumners et al. then conducted a series of studies using MIF to investigate its function on neurons.⁴³ They found that MIF, via its intrinsic thiol-protein oxidoreductase (TPOR), acted as an intracellular negative regulator of neuronal activity after the stimulation of Angiotensin II (Ang II), the hormone responsible for increased blood pressure.^44–46 This negative regulation was insufficient in spontaneously hypertensive rat neurons, because increased Ang II level did not elevate the expression of MIF and led to the chronotropic effect of Ang II.⁴⁷

Zis et al. discovered that the MIF content in cerebral blood vessel endothelial cells was significantly increased in ischemic stroke patients, and that the protective property was also observed in cultured cortical neuron model of oxygen-glucose deprivation (OGD) to mimic ischemia, treatment of MIF for 12 hours prevented OGD-induced cell death.⁴⁸ MIF depletion via shRNA in vitro or genetically modified animals was used to examine the effect of MIF on neuron cell death. The absence of MIF increased neuronal cell apoptotic caspase 3/7 activity,^13,49 and its presence rescued neurons from death by shifting the pro-/anti-apoptosis pathway balance to the survival side.⁵⁰ MIF treatment improved the proliferation and survival of neural stem/progenitor cells via many pathways, including PKB and extracellular regulated protein kinases (Erk), thereby extending these benefits to neural stem/progenitor cells.^49,51

In contrast to the positive effects, the detrimental aspects of MIF were also significant. Eric et al. found that after a single injection of 200 ng exogenous MIF into the mouse hippocampus, the pharmacological kinetics of induced N-methyl-D-aspartic acid receptor (NMDA) responses in the apical dendrites of hippocampal CA1 pyramidal neurons were altered for more than two weeks, which may be responsible for sequelae after CNS injury.⁵² In another rat diffuse axonal injury model, cortex MIF levels were considerably elevated 3 hours after injury and were primarily localized in neurons, intracerebroventricular injection of the MIF antagonist ISO-1 reduced neuronal apoptosis and axonal injury.⁵³ The similar neuronal cell death promotional effects of MIF were found to be involved in other studies, including the traumatic brain injury (TBI) model, which led to more severe neurodegeneration and neurologic deficits.^10,54

MIF accumulates in astrocytes and regulates its activity

The inhibitory effects of MIF on the reactivity of astrocytes were discovered as early as 1996.⁵⁵ In addition, MIF was found to be accumulated in astrocytes at the blood brain barrier (BBB) in the Borna disease virus (BDV) infected rat brain, where it modulates inflammation during virus-induced encephalitis. However, during BDV-induced inflammation, MIF in astrocytes was not produced at the gene level since MIF mRNA was absent in the experimental groups.⁵⁶ Recently, Okazaki and colleagues discovered that antipsychotics increased MIF expression in astrocytes via increasing the acetylation of H3K27 in the MIF promoter, indicating that MIF may play a role in the pathophysiology of schizophrenia disease and the working mechanisms of antipsychotics.⁵⁷

The promoting effects of MIF on astrocyte activity were investigated at the cellular level as well. Svenningsen et al. found that MIF and Serine protease high-temperature requirement A1 (HTRA1), a tumor suppressor implicated in cell growth and cerebral small vessel disease,⁵⁸ were both expressed in cultured mouse astrocytes.⁵⁹ HTRA1 can reduce astrocyte migration, whereas MIF inhibits this influence, which has potential benefits for CNS development and disease treatment.⁵⁹ The enhanced astrocyte proliferation phenomenon was also observed in a TBI mouse model, MIF concentrations were increased after traumatic brain injury and associated with poor outcome, and the pre-administration of MIF antagonist might prevent TBI induced astrocytosis.⁶⁰

MIF produced by microglia and involved in its inflammatory response

Previous studies have suggested that spinal microglia, not invading immune cells, create MIF in inflammatory hyperalgesia.^61,62 In primary cultured spinal microglia cells, MIF administration boosted COX2 expression and PGE2 production, while CD74 deletion completely reversed these effects.⁶³

Overall, the interactions of MIF with microglia are detrimental. The inhibition of MIF tautomerase activity downregulated LPS-induced nitro oxide (NO) and TNF-α production in microglial cells, indicating that MIF is involved in microglia-mediated neuron inflammatory pathology.⁶⁴ Zheng et al. found that Z-312, a novel MIF inhibitor, reduced proinflammatory factors produced by LPS-stimulated microglial cells in another LPS-induced PD mouse model.⁶⁵ Not surprisingly, MIF induced neuroinflammation and Parkinson's disease-like symptoms when microglial autophagy function was inhibited.⁶⁶ In addition to PD, the MIF level in glioblastoma patients was significantly elevated, and its expression in malignant gliomas exceeded that of normal brain tissue. The suppression of the MIF/CD74 pathway promoted interferon (IFN)- secretion in microglia, resulting in the death of tumor cells and a change from M2 to M1 in microglia associated with glioma.⁶⁷ Infusion of MIF into the animal hippocampus decreased microglia activation and prevented the production of microglia-derived tissue plasminogen activator, thereby protecting against excitotoxic neuronal cell death.⁴²

MIF involved in cerebrovascular structural cells dysfunction

Endothelial cells can release and respond to MIF when proatherogenic stimuli are present because they play a crucial structural function in blood vessel walls. Consequently, they can contribute to a number of vascular disorders, including atherosclerosis, retinopathy, and pulmonary hypertension.^68–70

MIF was expressed in the cerebral micro-vessels in the peri-infarct area of 10 acute stroke patients, in contrast to negative findings in normal brain.⁴⁸ The elevated expression of MIF in both the MCAo and OGD tests led to the discovery that MIF may stimulate angiogenesis via the AKT and ERK signaling pathways in rat brain microvascular endothelial cells.⁷¹ MIF levels in the blood of 39 stroke patients were also shown to be elevated; the subsequent investigation indicated that MIF injection disrupted tight junction in rat OGD-treated brain endothelial cells (ARBECs) and compromised BBB integrity in a tMCAo mice model.⁷² In experimental cerebral malaria produced by Plasmodium berghei ANKA, brain endothelial cells that displayed CD74 signaling contributed to the cross-presentation of antigens to CD8+ T lymphocytes, and pharmacologic Plasmodium MIF antagonism protected against cerebral malaria.⁷³

The mural cells of brain microvasculature is composed of pericytes and vascular smooth muscle cells (VSMCs).^74,75 Previous studies demonstrated that human placental NG2+ pericytes are the primary source of MIF in response to pathogenic activation, and these pericytes also offer migratory pathways for extravasated leukocytes in rat mesentery tissue and in vitro EC-PC barrier model.^76–78 Human VSMCs are likewise the secretory source of MIF under hypoxic conditions via HIF-1 activation,⁷⁹ with vascular remodeling properties through VSMC differentiation and proliferation interference in carotid and pulmonary arteries.^80,81 Nevertheless, the interaction of MIF with cerebrovascular pericytes and VSMCs remains limited. Greater comprehension of this topic will allow us to prevent BBB damage and hasten the recovery of the neurovascular unit after a stroke. The interaction of MIF with brain resident cells in experimental stroke were concluded in Table 2.

The function of MIF on brain injury

Dualistic roles of MIF on ischemic stroke

Although MIF depletion had no effect on cytokine levels in the brain or serum of mice one week after tMCAo,⁸² the detrimental effect of MIF on stroke recovery was found elsewhere.¹⁰ All the underlying mechanisms, including pro-inflammation, enhance immune reaction and accelerate neuron cell death, inhibit the recovery of post-stroke physiological function.^10,83–85 MIF levels were found to be considerably higher in acute ischemic stroke patients and in the experimental tMCAo model. The serum MIF levels of patients were positively correlated with infarct volume and long-term outcomes, while treatment of MIF increased BBB permeability in animal models following tMCAo.^72,86 Acute ischemic stroke patients with higher serum MIF concentrations at admission were more likely to have poor clinical outcome, post-stroke depression (PSD) and recurrent stroke in the long term,^87–89 and its major receptor CD74 was also found to have a similar predictive role in ischemic stroke patients.⁹⁰ In a different mouse focal ischemia model, knocking down MIF or inhibiting its nuclease activity decreased infarct volume and improved behavioral performance.⁹¹ Based on the nuclease property, the most recent work utilizing a photothrombotic ischemia model demonstrated that MIF acetylation on the K78 residue decreased the translocation and nuclear intensity of MIF, therefore providing a therapeutic target for protecting neurons in ischemic stroke.⁹²

MIF, on the other hand, has a neuroprotective effect in ischemic stroke by inhibiting neuronal cell death and inducing brain-derived neurotrophic factor (BDNF) expression.^12,50,93 It was found that 60 ng/mL MIF administration was most effective for BDNF expression and inhibiting neuronal apoptosis.⁹⁴ MIF promoted angiogenesis after ischemic stroke, this process could be inhibited by miR-493, which was previously thought to be a tumor angiogenesis suppressor.⁷¹ Furthermore, the deletion of MIF gene accelerated neuronal loss after stroke because MIF shielded neurons from oxidative stress and ischemia-reperfusion (I/R) induced apoptosis by reducing caspase-3 activation.¹³ HIF-1 activation boosted MIF promoter activity and dramatically reduced OGD-induced neuron cell death from a genetic perspective.⁴⁸ Finally, in the MCAo model, sex-specific protective benefits were discovered; MIF deletion was detrimental to female mice due to its involvement in regulating inflammation and cell death.⁹⁵

When examining particular genetically engineered ischemia models, we see that MIF-KO mice displayed smaller infarct volume at day 7 after 45 min tMCAo,¹⁰ with improved behavioral scores at day 1, 3, and 7 in the same surgical model, as reported by Wang's innovative study.⁹¹ However, another research found that MIF-KO mice had a larger infarct volume 10 hours after 2 hours of tMCAo, with no significant difference at 4 and 22 hours after ischemia.¹³ Similar outcomes were seen in MIF-KO mice administered 90 minutes of tMCAo on day 3, with the exception that females had bigger infarcts than WT females but males did not.⁹⁵ MIF appears to serve a protective effect at an early stage following prolonged ischemia, but no conclusion has been reached so far. Different observation timepoints, the length of occlusion, or even the origin of genetically engineered animals may account for contradictory MIF function results in ischemic stroke. Further research is required to evaluate the potential bias caused by the model discrepancies noted previously.

The double-faced role of MIF in hemorrhagic stroke

Blood MIF level was reported to be an ideal predictor of delayed cerebral ischemia (DCI) after acute stage of aneurysmal subarachnoid hemorrhage (aSAH), as reported by a single center, prospective, observational cohort study which enrolled 201 patients.⁹⁶ This positive correlation between serum MIF concentration and DCI after aSAH was postulated due to the inflammatory nature of MIF, which can exacerbate brain injury and stimulate the immune response during subarachnoid hemorrhage.⁹⁶ The difference between the two investigations was that the MIF concentration was measured in either cerebrospinal fluid (CSF) or normal pressure hydrocephalus.⁹⁷ These results were comparable to those of an earlier clinical trial using a small sample size. In the study, the MIF concentration in CSF was also identified as a biomarker for aSAH patients who suffered cerebral vasospasm (CV) and DCI sequelae. To obtain more convincing results, a multicenter study with a larger sample size of patients is still required. In patients with intracerebral hemorrhage (ICH), serum MIF concentration rose immediately after disease onset and was strongly correlated with plasma C-reactive protein level, hematoma size, and NIHSS score.¹⁵ Furthermore, it accurately reflected injury severity and can be used as an independent predictor of 6-month unfavorable outcome after acute ICH.⁹⁸

Interestingly, compared to clinical data, injecting 2 days before or 2 hours after bacterial collagenase induced experimental intracerebral hemorrhage, MIF alleviated ICH injury by inhibiting microglial activation and macrophage infiltration, resulting in lower reactive oxygen species (ROS) production and neuronal degeneration.^14,99

Evidence of MIF functions on traumatic brain injury

Possessing a similar predictive function as stroke, severe blunt trauma patients were also found had higher serum MIF concentrations and related to the clinical outcome.¹⁰⁰ Data from an observational study enrolled 116 severe TBI patients revealed that serum MIF concentrations were also a potential biomarker for identifying cerebrocardiac syndrome (CCS).¹⁰¹ Another study involving 108 severe TBI found a correlation between the serum MIF level and the severity of TBI and clinical outcomes.¹⁰² In sever blunt trauma patients, Chuang et al.

Wang et al. found that the total expression of MIF remained unchanged in a controlled cortical impact (CCI) induced TBI model.⁵⁴ However, MIF entered the nucleus of damaged neurons from the cytosol, causing neurodegeneration with a worsened neurological outcome in a poly ADP-ribose polymerase-1 (PARP-1) dependent manner.⁵⁴ Significantly, although MIF can promote neurodegeneration with the participation of CD74,¹⁰³ the treatment of MIF antagonist ISO1 failed to prevent neurodegeneration in the peri-injury cortex in a fluid percussion injury (FPI) model of TBI, despite the astrocyte suppression property of MIF during this process.⁶⁰

MIF and neurodegenerative diseases

Pleiotropic effects of MIF on Alzheimer’s disease

MIF levels in cerebral spinal fluid and resident brain cells were found to be increased in AD patients and could serve as a biomarker.¹⁰⁴ When compared 52 cognitively healthy volunteers to 97 cognitively impaired or mild dementia patients, the latter had higher MIF levels in CSF, which were significantly correlated with tau and phosphorylated tau protein level.¹⁰⁵ Similarly, another study involving 31 patients with AD, 28 patients with mild cognitive impairment (MCI) and 19 control participants showed that MIF concentrations in CSF were increased in both the AD and MCI groups, with a link between MIF and TNF-α levels in the AD group.¹⁰⁶

MIF was proved to be involved in neuroinflammation and cell toxicity in animal models of AD and in vitro studies.^107,108 Pharmacological MIF inhibition or knockout prevented tau protein hyperphosphorylation in C57BL/6 mice, along with better memory improvement in the same streptozotocin induced sporadic AD model.^107,109 After treatment with streptozotocin, extracellular MIF levels were considerably increased in cultured astrocytes and microglia, and the MIF antagonist ISO-1 decreased cytokine production in vitro.¹⁰⁷

In the Aβ1-40-stimulated PC12 cell line AD model, treatment with diabetes pathogenic compounds advanced glycation end products (AGEs) led to an increase in MIF expression and a decrease in PC12 cell viability.¹¹⁰ Consequently, the use of ISO-1 reversed AGEs induced cell deactivation and reduced inflammatory mediators such as IL-1β and TNF-α.¹¹⁰ In the early stage of AD brains, before the formation of AGEs, fluorescent phenylboronate gel electrophoresis¹¹¹ identified glucose-modified MIF that lacked the ability to stimulate enzymes and glial cells, suggesting that MIF participates in the entire progression of high glucose-induced AD-like changes. Using mass spectrometry-based imaging, Carlred et al. confirmed a high degree of co-localization of MIF and activated microglia to amyloid- (A) deposits in the hippocampal region, suggesting that MIF-associated neuroinflammation and glial cell reactivity played a crucial role in the AD pathology.¹¹² Notably, MIF deficiency impaired the spatial learning function of APP23 transgenic AD mice, suggesting that MIF can shield neuronal cells against A-induced cytotoxicity. The above evidence provides a more complete view of MIF in various AD models.¹¹³

The multifaced role of MIF on Parkinson’s disease

Prior to the year of 2000, the function of MIF on allogeneic fetal mesencephalic dopaminergic grafts was studied using the 6-hydroxydopamine rat model of PD.¹¹⁴ The intracerebral administration of MIF decreased the activities of microglia and macrophages but didn’t improve the function and survival of grafts.¹¹⁴ In 2011, Cheng et al. compared 92 PD patients with 87 matched controls and revealed a significant elevation of serum MIF levels in PD patients, proposing MIF levels as a diagnostic biomarker for PD.¹¹⁵ All clinical studies mentioned in this review were summarized in Table 1.

Table 1.

Clinical investigations of the relationship between MIF and brain injury.

Disease	Publishing year	Study type and subjects	Clinical samples collection methods	Major findings
Ischemic stroke	Liu et al. 2018⁶⁴	Prospective observational study, single center, 39 patients and 14 healthy donors	Blood samples were collected from ischemic stroke patients tPA injection	Plasma MIF level was markedly elevated in the stroke patients
	Wang et al. 2009⁶⁵	Observational, single center, 102 patients and 57 controls	Not mentioned	The MIF protein level, mRNA levels in PBMCs were significantly higher in the patients than in the controls
	Wang et al. 2019⁶⁶	Prospective cohort study with a follow-up for a median of 12 months, single center, 469 patients with ischemic stroke and 423 completed follow-ups	Blood samples from some patients (N = 33) were collected on 12 h, 24 h, 48 h, 72 h, and 96 h after admission for MIF test	Serum levels of MIF increased with increasing severity of stroke and associated with increased risk of stroke recurrence in the next 12 months
	Xu et al. 2018⁶⁷	Prospective cohort study with a follow-up of 3 months, single center, 333 patients and 100 healthy volunteers with a three-month follow-up	Fasting blood was collected at 6:00 am on the morning after the admission	Plasma MIF levels were highly associated with infarct volumes and NIHSS score, elevated plasma levels of MIF at admission were associated with increased risk of PSD in the next three months
	Wang et al. 2019⁶⁸	Cross-sectional study, single center, 289 patients	Serum was collected under fasting at 8:00 on the first morning of admission and at 12, 24, 48 and 72 h after admission for MIF test	High serum MIF level of stroke patients may be an independent predictor for the moderate to high clinical severity and poor early outcome
	Yang et al. 2017⁶⁹	Prospective cohort study, single center, 20 stroke subjects and 14 controls	Peripheral blood samples were collected from healthy control subjects and ischemic stroke subjects at the time of admission	Plasma levels of MIF and the number of CD74-expressing PBMCs were significantly increased in subjects with ischemic stroke at admission, CD74 expression was correlated with stroke severity
Hemorrhagic stroke	Yang et al. 2020⁷⁴	Prospective cohort study with 3 month follow-up, single center, 201 aSAH patients	Fasting serum samples were collected at 6:00 am on the first morning after the admission	Higher level of serum MIF was an independent predictor of DCI in aSAH
	Kwan et al. 2019⁷⁵	Prospective cohort study, single center, 25 patients in the aSAH group and 9 in the normal pressure hydrocephalus group	CSF was collected from aSAH patients every other day for 13 days from the time of admission up to 72 hours and from NPH patients for 3 days until the lumbar drain was discontinued	CSF MIF concentration in patients with aSAH was significantly higher than those with normal pressure hydrocephalus, CSF concentrations of MIF are correlated with CV and DCI
	Lin et al. 2017⁷⁶	Prospective observational study with a follow-up for 6 months, single center, 120 consecutive ICH patients and 120 healthy controls	Blood samples were obtained at admission for the patients	MIF in serum was identified as an independent predictor for 6-month overall survival and 6-month unfavorable outcome after acute ICH
Traumatic brain injury	Chuang et al. 2004⁷⁸	Prospective observational study, single center, 54 severe blunt trauma patients and 44 patients with minor injuries as controls	Peripheral venous blood samples were obtained in the emergency department <4 hrs postinjury (day 1) and the surgical intensive care unit 24 hrs later (day 2)	Serum MIF concentration was higher in severe blunt trauma and correlated with SIRS
	Dai et al. 2021⁷⁹	prospective observational study, single center, 116 severe TBI patients and 116 healthy controls	Blood samples were collected from controls at study entrance and those of patients were obtained at their arrival to emergency department	Increased serum MIF concentration is independently related to degree of neuroinflammation, clinical severity and risk of cerebrocardiac syndrome in severe TBI patients
	Yang et al. 2017⁸⁰	Prospective observational study with a follow-up for 6 months, single center, 108 severe TBI patients and 108 controls	Venous blood was drawn from patients on admission and from controls at study entry	Serum MIF concentrations had close relation to white blood cell count and serum CRP, IL-6 and TNF-α, and it was an independent predictor for long-term prognosis and in-hospital major adverse events

MIF: macrophage migration inhibitory factor; tPA: tissue plasminogen activator; PBMCs: Peripheral blood mononuclear cells; NIHSS: National Institute of Health stroke scale; PSD: post-stroke depression; aSAH: aneurysmal subarachnoid hemorrhage; DCI: delayed cerebral ischemia; CV: cerebral vasospasm; DCI: delayed cerebral ischemia; CSF: colony stimulating factor; ICH: intracranial hemorrhage; TBI: traumatic brain injury; CRP: C-reactive protein; SIRS: systemic inflammatory response syndrome.

Table 2.

The dualistic effects of MIF on brain resident cells in experimental stroke.

Brain cells	Study objects	Major findings	Mechanisms	Time point of main treatment	Duration of brain injury after in vivo model onset
Neuronal cells	Totoxin-induced hippocampus neurodegeneration³⁵	Pretreatment of MIF protect neuronal cell from death	MIF inhibited microglial activation and the subsequent release of tissue plasminogen activator	Two days infusion of 500 μM MIF before the injection of kainate	5 days
	Rat hypothalamus–brainstem neuronal cell cultures^38,40	Increased levels of intracellular MIF inhibited the stimulatory actions of Ang II on neuronal firing	The inhibitory actions are mediated via a thiol-oxidoreductase activity of the MIF molecule and subsequent scavenging of ROS	Neuronal cultures were pretreated with Ang II for 5 hours	/
	Cortical neurons of E18–E19 rat embryos⁴¹	MIF significantly protected neurons against OGD-induced cell death and lower cell viability	Not deeply investigated	Simultaneously treated with OGD and 50 or 100 ng/mL human MIF	/
	Human neuroblastoma cell line; mice tMCAO model¹³	MIF’s protection of neuronal cell occurs relatively early following stroke (within 10 h) and diminished at late phase (24 h) in vivo	Reduced caspase-3 activation	Simultaneously treated with OGD and human MIF at a concentration of 200 ng/ml in vitro; using MIF-knockout mice in vivo study	4 and 22 hours
	Mice neural stem/progenitor cells⁴²	MIF contributed to neural stem/progenitor cells proliferation, survival and migration	MIF increased the phosphorylation of AKT, ERK, AMPK and STAT3; MIF knockdown by shRNA increased caspase 3/7 activity	3 days treatment of MIF (400 ng/ml)	/
	Human neuroblastoma cell line⁴³	MIF promoted cell survival in OGD treated neuroblastoma cells	Induced the expression of mature BDNF, MAP2 and Bcl2, and decreased the expression of Caspase-3 and Bax	30 ng/ml MIF after 4 hours of OGD	/
	Kunming mice and hippocampuscells⁴⁴	MIF Is Expressed in NeuN-Positive, NeuN-Negative, and Granule cells in Developing Hippocampus	MIF antagonist suppressed cell proliferation in the developing hippocampus in vivo and hinders neurite outgrowth in vitro	Inject ISO-1 into Postnatal day 5 mice for 9 consecutive days; primary neuronal cultures with ISO-1 using 10 or 100 µM for 2 days	/
	Adult male C57BL/6 mice⁴⁵	MIF significantly increased the baseline frequency of Ca2+ events in mouse hippocampal CA1 layer pyramidal neurons	Possibly via an interaction with Kv channels, might directly promoted epileptogenic activity in the hippocampus	Injected 200 ng recombinant MIF into the CA1 region of the hippocampus	14 days
	Rat with diffuse axonal injury (DAI)⁴⁶	MIF was increased and peaked at 1 d after DAI; inhibition of MIF exhibited decreased apoptosis, axonal injury, and glial response	Increased levels of IL-6, IL-1β, and TNF-α through TLR-related pathways following DAI	Injected intracerebroventricularly with 10 μL ISO-1 mixture 0.5 h before modeling	1 day
	TBI mouse model⁴⁷	MIF KO protected dendritic spine density and morphological complexity in neurons and reduced neuronal cell death following TBI	Through MIF nuclease activity rather than pro-infammatory role	MIF KO mice and nuclease-defcient E22A MIF mutant	1 day
Astrocyte	Adult retired female breeders of the CD1 strain⁴⁸	MIF reduced astroglial reactivity	Not deeply investigated	Single application of 500 μM MIF	4 days
	Borna Disease Virus infected rat model⁴⁹	MIF protein accumulation in astrocytes and infifiltration of ED1-positive macrophages	MIF from neurons or other extracellular sources into astrocytes at Blood-Brain Barrier	No specific treatment	22 days
	Astrocytes of P1–P5 mice⁵¹	MIF rescued HTRA1-inhibited astrocyte migration	The binding between MIF and HTRA1 was to inhibit the proteolytic activity of HTRA1	Simultaneously treatment of HTRA1 and 50 ng/mL MIF	/
	Male C57BL/6J mice with Fluid Percussion Injury (FPI) Model of TBI⁵²	ISO-1 reduced astrocyte activation but had no signifificant effffect on neurodegeneration	Not deeply investigated	Injected 10 mg/kg ISO1 at 30 min after TBI	3 days
Microglia	LPS treated murine microglia cell line and mouse neuroblastoma cell line⁵⁶	MIF Inhibitor Z-590 attenuated the microglia-mediated neurotoxicity to HT-22 neuroblastoma cells	Z-590 decreased the production of NO, TNF-α, IL-6, IL-1β, COX-2, iNOS and ROS involved in inhibiting MAKPs signaling pathway in LPS-stimulated microglia cells	30 min Z-590 (5–20 μM) prior to and during incubation with LPS (200 ng/mL) or vehicle for an additional 16 h	/
	LPS treated murine microglia cell line and mouse neuroblastoma cell line, and C57BL/6 mice⁵⁷	MIF Inhibitor Z-312 suppressed the neurotoxic effects in vitro, and ameliorated microglial activation and subsequent DA neuron loss	Z-312 significantly decreased the production of NO, IL-1β, TNF-α and IL-6	30 min Z-312 before adding 200 ng/mL of LPS in vitro, intraperitoneally administered Z-312 (20 mg/kg/d) for 10 consecutive days before LPS treatment in vivo	8 days
	Murine glioma and microglia cell lines, rat glioma cell line and human glioma cell line; C57BL/6 mice⁵⁹	The inhibition of MIF or its receptor CD74 promoted IFN-γ release and amplified tumor death as well as inducing a M2 to M1 shift in glioma-associated microglia	MIF-CD74 signaling inhibited interferon (IFN)-γ secretion in microglia through phosphorylation of microglial ERK1/2	MIF-overexpressing or knockdown and CD74 antibody were used	5 days
Endothelial cells	Rat with tMCAO and rat brain microvascular endothelial cells⁶⁷	The protective effect of miR-493 inhibition in angiogenesis was attenuated by knocking down MIF	MiR-493 directly modulated MIF expression	Knockout MIF before treatment of miR-493 inhibition	3 days
	Rats with tMCAO and pMCAO, and rat brain endothelial cells⁶⁸	MIF increased BBB permeability and exacerbates stroke injury	MIF led to the disruption of tight junction	MIF were given after MCAO (20 µg/kg) or OGD treatment	4h for permeability; 24 h for infarct volume
	Mice infected with Plasmodium berghei ANKA⁶⁹	Cd74^−/− mice is resistant to experimental cerebral malaria	Cross-presentation of Plasmodium antigen is MIF/CD74 signaling dependent	Pharmacologic Plasmodium MIF antagonism before infection and continued treatment once daily for 2 days	7 days

ERK: extracellular regulated protein kinases; MAPK: mitogen-activated protein kinase; STAT: Signal Transducers and Activators of Transcription; DAI: diffuse axonal injury; BDNF: brain derived neurotrophic factor; MAP2: microtubule association protein-2; FPI: fluid percussion injury; HTRA: high-temperature requirement A1; NO: nitro oxide; TNF: tumor necrosis factor; iNOS: inducible nitric oxide synthase; ROS: reactive oxygen species; BBB: blood brain barrier; LPS: lipopolysaccharide.

In Atg5 conditional knockout mice, the deficiency of microglial autophagy led to an increase of MIF in a NLRP3 inflammasome, causing neuroinflammation and PD-like symptoms.⁶⁶ The MAPKs and NF-κB pathways were implicated in the MIF related LPS-induced PD mouse model.⁶⁵ In co-culturing BV-2 microglia and HT22 neuroblastoma cells, the use of a MIF small-molecule inhibitor Z-312 attenuated LPS-induced neurotoxicity with decreased proinflammatory factors; this protective effect of Z-312 was also demonstrated in vivo by a decrease in LPS-induced dopaminergic neuronal loss.⁶⁵ For the α-synuclein (α-syn) preformed fibril (PFF) mouse model of sporadic PD, it was recently revealed that genetic and pharmacological inhibition of MIF nuclease activity can prevent neurodegeneration by decreasing PARP-1 activity.¹¹⁶

Compared with the negative influence on PD pathology above, MIF’s expression was found to be positively correlated with IL-10 and to inhibit apoptosis in SH-SY5Y PD cells via decreasing the concentration of cleaved-PARP. Moreover, MIF enhanced autophagosome production in the SH-SY5Y PD cell model, which may be advantageous for neurodegenerative diseases such as PD.¹¹⁷ Another neuroprotective effect of MIF was the ability to protect amino acid decarboxylase (AADC)-expressing Chinese hamster ovary (CHO) cells treated with MIF from intracellular but not extracellular dopamine toxicity.¹¹⁸ Figure 2 shows how MIF interact with AD and PD.

Figure 2.

The double-sided effects of MIF on neurodegenerative disease models. MIF exerts protective effects by inhibiting Aβ-induced cytotoxicity, increasing anti-inflammatory cytokine IL-10 release, promoting autophagosome formation, and reducing intracellular dopamine toxicity in AD and PD models. In terms of the detrimental side, MIF is correlated to tau protein hyperphosphorylation, inflammatory cytokines production, microglial activation, and PARP-1 stimulation. Aβ: amyloid β-protein; AD: Alzheimer’s disease; PD: Parkinsons; PARP-1: poly ADP-ribose polymerase-1 (PARP-1); DA neuron: dopaminergic neuron. The figure were created with BioRender.com.

As previously stated, MIF is a diverse and contentious cytokine in both physiology and pathology. As illness progresses, MIF may display distinct roles in different cell contexts; hence, the impact of varied dosages of MIF on disease progression should not be overlooked.

Concluding remarks

Due to its proinflammatory characteristics, MIF was previously assumed to be deleterious in brain disorders. Recent research has demonstrated that MIF modulation effects are diverse, and that MIF may possibly have organ protective properties in brain damage and neurodegenerative disorders. However, the advantages of MIF in neuroinflammatory diseases were mainly found in basic research, and the specific type of disease model may also influence the explanation of the results. As the numerous activities of MIF in the development of brain damage and neurodegenerative disorders are elucidated, MIF has emerged as a novel and appealing therapeutic target. In MIF-based pharmacological methods, anti-MIF monoclonal antibody, antibodies directed against MIF receptors, and small-molecule inhibitors have been created.^119,120 However, there are still limits to these pharmaceutical techniques. Synthesis inhibitors, for instance, may target an array of downstream pathways and lack selectivity. Therefore, MIF must be carefully targeted based on its varied functions.

In this review, we highlight the novel findings of MIF mechanistic insights in immune cells participating in acute and chronic brain disorders, which may shed light on MIF as a prospective therapeutic target in the future.

Footnotes

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: P L. is supported by the National Natural Science Foundation of China (NSFC, 81722017, 91957111, 81971096, 82061130224), New Frontier Technology Joint Research (SHDC12019102) and Ward Building Project for Demonstration and Research sponsored by Shanghai Shenkang Hospital Development Center, Shanghai Municipal Education Commission-Gaofeng Clinical Medical Grant Support (20181805), Shuguang Program supported by Shanghai Education Development Foundation and Shanghai Municipal Education Commission (20SG17), Shanghai Outstanding Academic Leaders’ Program from Shanghai Municipal Science and Technology Committee (20XD1422400), Newton Advanced Fellowship grant provided by the UK Academy of Medical Sciences (NAF\R11\1010), and Renji Clinical Research Funding (PYII20-03) the Innovative Research Team of High-level Local Universities in Shanghai (SHSMU-ZLCX20211602). W.Y. is supported by the Shanghai Pudong New Area Municipal Commission of Health and Family Planning Funding (PWZxq2017-06). Shanghai Municipal Key Clinical Specialty (shslczdzk03601 to Weifeng Yu.), Shanghai Engineering Research Center of Peri-operative Organ Support and Function Preservation (20DZ2254200). W.X. is supported by the National Natural Science Foundation of China (NSFC, 81901985).

Acknowledgements

Thank the authors of the references.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ORCID iDs

Yuxuan Lin

Peiying Li

References

David

JR.

Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966; 56: 72–77.

Bach

Deuster

Balzer-Geldsetzer

, et al. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009; 115: 2031–2040.

Nishihira

Koyama

Mizue

Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998; 10: 199–205.

Pan

Sukhova

Yang

, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2004; 109: 3149–3153.

Ogata

Nishihira

Suzuki

, et al. Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci Lett 1998; 246: 173–177.

Kudrin

Ray

Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol 2008; 86: 232–238.

Bacher

Meinhardt

Lan

, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998; 4: 217–230.

Stefaniak

Schiefer

Miller

, et al. Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation. Liver Transpl 2015; 21: 662–669.

Noels

Bernhagen

Weber

Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 2009; 19: 76–86.

10.

Inácio

Ruscher

Leng

, et al. Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke. J Cereb Blood Flow Metab 2011; 31: 1093–1106.

11.

Zhang

, et al. Downregulation of microRNA‑451 improves cell migration, invasion and tube formation in hypoxia‑treated HUVECs by targeting MIF. Mol Med Rep 2019; 20: 1167–1177.

12.

Chang

Park

Rhie

, et al. Early treadmill exercise increases macrophage migration inhibitory factor expression after cerebral ischemia/reperfusion. Neural Regen Res 2019; 14: 1230–1236.

13.

Zhang

Zis

, et al. Down-regulation of MIF by NFκB under hypoxia accelerated neuronal loss during stroke. FASEB J 2014; 28: 4394–4407.

14.

Wang

Tsirka

SE.

Tuftsin fragment 1-3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke 2005; 36: 613–618.

15.

Bernhagen

Mitchell

Calandra

, et al. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994; 33: 14144–14155.

16.

Baugh

Chitnis

Donnelly

, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002; 3: 170–176.

17.

Günther

Fagone

Jalce

, et al. Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. Drug Discov Today 2019; 24: 428–439.

18.

Arizza

Bonura

La Paglia

, et al. Transcriptional and in silico analyses of MIF cytokine and TLR signalling interplay in the LPS inflammatory response of Ciona robusta. Sci Rep 2020; 10: 11339.

19.

Rice

Tesch

Cao

, et al. Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney Int 2003; 63: 1265–1275.

20.

Leng

Metz

Fang

, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197: 1467–1476.

21.

Alampour-Rajabi

Bounkari

Rot

, et al. MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis. FASEB J 2015; 29: 4497–4511.

22.

Bernhagen

Krohn

Lue

, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587–596.

23.

Gore

Starlets

Maharshak

, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008; 283: 2784–2792.

24.

Lue

Thiele

Franz

, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007; 26: 5046–5059.

25.

Shi

Leng

Wang

, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006; 25: 595–606.

26.

Simi

Ingelman-Sundberg

Tindberg

Neuroprotective agent chlomethiazole attenuates c-fos, c-jun, and AP-1 activation through inhibition of p38 MAP kinase. J Cereb Blood Flow Metab 2000; 20: 1077–1088.

27.

Wen

Cai

Yang

, et al. Targeting macrophage migration inhibitory factor in acute pancreatitis and pancreatic cancer. Front Pharmacol 2021; 12: 638950.

28.

Bemis

Chan

Finkielstein

, et al. Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev 2004; 18: 739–744.

29.

Décaillot

Kazmi

Lin

, et al. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem 2011; 286: 32188–32197.

30.

Liu

Song

Guo

, et al. CXCL12/CXCR4 signaling contributes to neuropathic pain via Central sensitization mechanisms in a rat spinal nerve ligation model. CNS Neurosci Ther 2019; 25: 922–936.

31.

Saha

Ahn

Blando

, et al. Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice. Cancer Res 2017; 77: 5158–5168.

32.

Huang

Wan

Mao

, et al. Inhibiting the migration of M1 microglia at hyperacute period could improve outcome of tMCAO rats. CNS Neurosci Ther 2017; 23: 222–232.

33.

Rafiei

Gui

, et al. Targeting the MIF/CXCR7/AKT signaling pathway in castration-resistant prostate cancer. Mol Cancer Res 2019; 17: 263–276.

34.

Meiklejohn

Coley

Pressor and catecholamine response to nasal intubation of the trachea. Br J Anaesth 1989; 63: 283–286.

35.

West

Parker

Ward

, et al. Differential and cell-type specific regulation of responses to toll-like receptor agonists by ISO-1. Immunology 2008; 125: 101–110.

36.

Kurita

Yamashiro

Kuroki

, et al. Metabolic endotoxemia promotes neuroinflammation after focal cerebral ischemia. J Cereb Blood Flow Metab 2020; 40: 2505–2520.

37.

Shin

Kang

Wahl

, et al. Macrophage migration inhibitory factor regulates U1 small nuclear RNP immune complex-mediated activation of the NLRP3 inflammasome. Arthritis Rheumatol 2019; 71: 109–120.

38.

Lang

Lee

JPW

Elgass

, et al. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat Commun 2018; 9: 2223.

39.

Baugh

Gantier

, et al. Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun 2006; 347: 895–903.

40.

Morand

Leech

Bernhagen

MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006; 5: 399–410.

41.

Aeberli

Leech

Morand

EF.

Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 2006; 45: 937–943.

42.

Rogove

Tsirka

SE.

Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 1998; 8: 19–25.

43.

Matsuura

Sun

Leng

, et al. Macrophage migration inhibitory factor increases neuronal delayed rectifier K+ current. J Neurophysiol 2006; 95: 1042–1048.

44.

Busche

Gallinat

Fleegal

, et al. Novel role of macrophage migration inhibitory factor in angiotensin II regulation of neuromodulation in rat brain. Endocrinology 2001; 142: 4623–4630.

45.

Sun

Leng

, et al. Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity. J Neurosci 2004; 24: 9944–9952.

46.

Matsuura

Harrison

Westwell

, et al. Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are regulated by thioredoxin. Am J Physiol Cell Physiol 2007; 293: C211–217.

47.

Sun

Gao

, et al. Lack of macrophage migration inhibitory factor regulation is linked to the increased chronotropic action of angiotensin II in SHR neurons. Hypertension 2007; 49: 528–534.

48.

Zis

Zhang

Dorovini-Zis

, et al. Hypoxia signaling regulates macrophage migration inhibitory factor (MIF) expression in stroke. Mol Neurobiol 2015; 51: 155–167.

49.

Ohta

Misawa

Fukaya

, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci 2012; 125: 3210–3220.

50.

Bae

Yoo

Kim

, et al. Brain-derived neurotrophic factor mediates macrophage migration inhibitory factor to protect neurons against oxygen-glucose deprivation. Neural Regen Res 2020; 15: 1483–1489.

51.

Chai

Zhang

, et al. Profile of MIF in developing hippocampus: association with cell proliferation and neurite outgrowth. Front Mol Neurosci 2020; 13: 147.

52.

Bancroft

Srinivasan

Shapiro

LA.

Macrophage migration inhibitory factor alters functional properties of CA1 hippocampal neurons in mouse brain slices. Int J Mol Sci 2019; 21: 276.

53.

Zhao

Wei

, et al. Inhibition of macrophage migration inhibitory factor protects against inflammation through a toll-like receptor-related pathway after diffuse axonal injury in rats. Biomed Res Int 2020; 2020: 5946205.

54.

Ruan

Wang

, et al. MIF promotes neurodegeneration and cell death via its nuclease activity following traumatic brain injury. Cell Mol Life Sci 2021; 79: 39.

55.

Balasingam

Yong

VW.

Attenuation of astroglial reactivity by interleukin-10. J Neurosci 1996; 16: 2945–2955.

56.

Bacher

Weihe

Dietzschold

, et al. Borna disease virus-induced accumulation of macrophage migration inhibitory factor in rat brain astrocytes is associated with inhibition of macrophage infiltration. Glia 2002; 37: 291–306.

57.

Okazaki

Boku

Otsuka

, et al. Clozapine increases macrophage migration inhibitory factor (MIF) expression via increasing histone acetylation of MIF promoter in astrocytes. J Psychiatr Res 2021; 135: 237–242.

58.

Di Donato

Bianchi

Gallus

, et al. Heterozygous mutations of HTRA1 gene in patients with familial cerebral small vessel disease. CNS Neurosci Ther 2017; 23: 759–765.

59.

Fex Svenningsen

Löring

Sørensen

, et al. Macrophage migration inhibitory factor (MIF) modulates trophic signaling through interaction with serine protease HTRA1. Cell Mol Life Sci 2017; 74: 4561–4572.

60.

Newell-Rogers

Rogers

Tobin

, et al. Antagonism of macrophage migration inhibitory factory (MIF) after traumatic brain injury ameliorates astrocytosis and peripheral lymphocyte activation and expansion. Int J Mol Sci 2020; 21: 7448.

61.

Koda

Nishio

Hashimoto

, et al. Up-regulation of macrophage migration-inhibitory factor expression after compression-induced spinal cord injury in rats. Acta Neuropathol 2004; 108: 31–36.

62.

Wang

Shen

Guo

, et al. Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats. Pain 2010; 148: 275–283.

63.

Wang

, et al. Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia. Neurosci Res 2011; 71: 210–218.

64.

Zhang

Jia

, et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity suppresses microglia-mediated inflammatory responses. Clin Exp Pharmacol Physiol 2016; 43: 1134–1144.

65.

Zheng

Chen

Zhang

, et al. Inhibition of neuroinflammation by MIF inhibitor 3-({[4-(4-methoxyphenyl)-6-methyl-2-pyrimidinyl]thio}1methyl)benzoic acid (Z-312). Int Immunopharmacol 2021; 98: 107868.

66.

Cheng

Liao

Dong

, et al. Microglial autophagy defect causes Parkinson disease-like symptoms by accelerating inflammasome activation in mice. Autophagy 2020; 16: 2193–2205.

67.

Ghoochani

Schwarz

Yakubov

, et al. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. Oncogene 2016; 35: 6246–6261.

68.

Wang

Lin

Kaiser

, et al. Absence of macrophage migration inhibitory factor reduces proliferative retinopathy in a mouse model. Acta Diabetol 2017; 54: 383–392.

69.

Zernecke

Bernhagen

Weber

Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594–1602.

70.

Le Hiress

Ricard

, et al. Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/CD74 complex. Am J Respir Crit Care Med 2015; 192: 983–997.

71.

Baral

, et al. MicroRNA-493 regulates angiogenesis in a rat model of ischemic stroke by targeting MIF. FEBS J 2016; 283: 1720–1733.

72.

Liu

Tsai

Tang

, et al. Cytokine MIF enhances blood-brain barrier permeability: impact for therapy in ischemic stroke. Sci Rep 2018; 8: 743.

73.

B, Garcia

Siu

, et al. Suppression of plasmodium MIF-CD74 signaling protects against severe malaria. FASEB J 2021; 35: e21997.

74.

Kaplan

Chow

Neuronal regulation of the blood-brain barrier and neurovascular coupling. Nat Rev Neurosci 2020; 21: 416–432.

75.

Vazquez-Liebanas

Nahar

Bertuzzi

, et al. Adult-induced genetic ablation distinguishes PDGFB roles in blood-brain barrier maintenance and development. J Cereb Blood Flow Metab 2022; 42: 264–279.

76.

Stark

Eckart

Haidari

, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct' them with pattern-recognition and motility programs. Nat Immunol 2013; 14: 41–51.

77.

Murfee

Skalak

Peirce

SM.

Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. Microcirculation 2005; 12: 151–160.

78.

Pellowe

Sauler

Hou

, et al. Endothelial cell-secreted MIF reduces pericyte contractility and enhances neutrophil extravasation. FASEB J 2019; 33: 2171–2186.

79.

Luo

Yang

, et al. Hypoxia stimulates the expression of macrophage migration inhibitory factor in human vascular smooth muscle cells via HIF-1alpha dependent pathway. BMC Cell Biol 2010; 11: 66.

80.

Fan

Zhang

Chen

, et al. Macrophage migration inhibitory factor triggers vascular smooth muscle cell dedifferentiation by a p68-serum response factor axis. Cardiovasc Res 2017; 113: 519–530.

81.

Huang

Chen

, et al. The small molecule macrophage migration inhibitory factor antagonist MIF098, inhibits pulmonary hypertension associated with murine SLE. Int Immunopharmacol 2019; 76: 105874.

82.

Inácio

Bucala

Deierborg

Lack of macrophage migration inhibitory factor in mice does not affect hallmarks of the inflammatory/immune response during the first week after stroke. J Neuroinflammation 2011; 8: 75.

83.

Inácio

Ruscher

Wieloch

Enriched environment downregulates macrophage migration inhibitory factor and increases parvalbumin in the brain following experimental stroke. Neurobiol Dis 2011; 41: 270–278.

84.

Chen

, et al. Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS One 2012; 7: e40165.

85.

Wang

, et al. DRα1-MOG-35-55 reduces permanent ischemic brain injury. Transl Stroke Res 2017; 8: 284–293.

86.

Wang

Zis

, et al. Upregulation of macrophage migration inhibitory factor gene expression in stroke. Stroke 2009; 40: 973–976.

87.

Wang

Liu

, et al. Macrophage migration inhibitory factor levels correlate with stroke recurrence in patients with ischemic stroke. Neurotox Res 2019; 36: 1–11.

88.

, et al. Elevated plasma macrophage migration inhibitor factor as a risk factor for the development of post-stroke depression in ischemic stroke. J Neuroimmunol 2018; 320: 58–63.

89.

Wang

C-W

P-J

Wang

Y-Y

, et al. Serum level of macrophage migration inhibitory factor predicts severity and prognosis in patients with ischemic stroke. Cytokine 2019; 115: 8–12.

90.

Yang

Kong

Ren

, et al. Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke. Neurochem Int 2017; 107: 148–155.

91.

Wang

Umanah

, et al. A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science 2016; 354: aad6872.

92.

, et al. Macrophage migration inhibitory factor (MIF) acetylation protects neurons from ischemic injury. Cell Death Dis 2022; 13: 466.

93.

Kim

Lee

, et al. Neuroprotective effect of macrophage migration inhibitory factor (MIF) in a mouse model of ischemic stroke. Int J Mol Sci 2022; 23: 6975.

94.

Jung

Kim

, et al. Determining the optimal administration conditions under which MIF exerts neuroprotective effects by inducing BDNF expression and inhibiting apoptosis in an in vitro stroke model. Brain Sci 2021; 11: 280.

95.

Turtzo

Persky

, et al. Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice. Neurobiol Dis 2013; 54: 421–431.

96.

Yang

Peng

Pang

, et al. The association between serum macrophage migration inhibitory factor and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurotox Res 2020; 37: 397–405.

97.

Kwan

Arapi

Wagner

, et al. Cerebrospinal fluid macrophage migration inhibitory factor: a potential predictor of cerebral vasospasm and clinical outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 2019; 133: 1786–1791.

98.

Lin

Cai

, et al. Macrophage migration inhibitory factor levels in serum from patients with acute intracerebral hemorrhage: Potential contribution to prognosis. Clin Chim Acta 2017; 472: 58–63.

99.

Wang

Rogove

Tsirka

, et al. Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage. Ann Neurol 2003; 54: 655–664.

100.

Chuang

Hung

Tsai

, et al. High concentrations of circulating macrophage migration inhibitory factor in patients with severe blunt trauma: is serum macrophage migration inhibitory factor concentration a valuable prognostic factor? Crit Care Med 2004; 32: 734–739.

101.

Dai

Lin

, et al. Utility of serum macrophage migration inhibitory factor as a potential biomarker for detection of cerebrocardiac syndrome following severe traumatic brain injury. Clin Chim Acta 2021; 512: 179–184.

102.

Yang

Dong

, et al. Serum macrophage migration inhibitory factor concentrations correlate with prognosis of traumatic brain injury. Clin Chim Acta 2017; 469: 99–104.

103.

Tobin

Mukherjee

Kain

, et al. Traumatic brain injury causes selective, CD74-dependent peripheral lymphocyte activation that exacerbates neurodegeneration. Acta Neuropathol Commun 2014; 2143.

104.

Bacher

Deuster

Aljabari

, et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med 2010; 16: 116–121.

105.

Oikonomidi

Tautvydaitė

Gholamrezaee

, et al. Macrophage migration inhibitory factor is associated with biomarkers of Alzheimer's disease pathology and predicts cognitive decline in mild cognitive impairment and mild dementia. JAD 2017; 60: 273–281.

106.

Popp

Bacher

Kölsch

, et al. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2009; 43: 749–753.

107.

Nasiri

Sankowski

Dietrich

, et al. Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. Mol Med 2020; 26: 34.

108.

Liang

Zhang

, et al. Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease. Acta Pharmacol Sin 2018; 39: 1421–1438.

109.

Han

, et al. Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer's disease. J Neuroinflammation 2015; 12: 177.

110.

Zang

, et al. Protective effect of ISO‑1 against advanced glycation end product aggravation of PC12 cell injury induced by Aβ1‑40. Mol Med Rep 2019; 20: 2135–2142.

111.

Kassaar

P Morais

, et al. Macrophage migration inhibitory factor is subjected to glucose modification and oxidation in Alzheimer's disease. Sci Rep 2017; 7: 42874.

112.

Carlred

Michno

Kaya

, et al. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry. J Neurochem 2016; 138: 469–478.

113.

Zhang

Zhao

Zhang

, et al. Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer's disease. Alzheimers Res Ther 2019; 11: 54.

114.

Schwarz

Sautter

, et al. Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine rat model of Parkinson's disease. Exp Brain Res 1998; 120: 95–103.

115.

Nicoletti

Fagone

Donzuso

, et al. Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine 2011; 55: 165–167.

116.

Park

Kam

Peng

, et al. PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson's disease. Cell 2022; 185: 1943–1959.e21.

117.

Nie

Zhang

, et al. Macrophage migration inhibitory factor mediates neuroprotective effects by regulating inflammation, apoptosis and autophagy in Parkinson's disease. Neuroscience 2019; 416: 50–62.

118.

Weingarten

Zhou

QY.

Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J Neurochem 2001; 77: 776–785.

119.

Sumaiya

Langford

Natarajaseenivasan

, et al. Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther 2022; 233: 108024.

120.

Kang

Bucala

The immunobiology of MIF: function, genetics and prospects for precision medicine. Nat Rev Rheumatol 2019; 15: 427–437.

Dualistic roles and mechanistic insights of macrophage migration inhibitory factor in brain injury and neurodegenerative diseases

Abstract

Keywords

Introduction

Regulatory mechanisms of MIF expression under different pathological contexts

The intracellular downstream signals of MIF

Divergent pathological mechanisms of MIF in different brain resident cells

Double side effects on neuronal cells

MIF accumulates in astrocytes and regulates its activity

MIF produced by microglia and involved in its inflammatory response

MIF involved in cerebrovascular structural cells dysfunction

The function of MIF on brain injury

Dualistic roles of MIF on ischemic stroke

The double-faced role of MIF in hemorrhagic stroke

Evidence of MIF functions on traumatic brain injury

MIF and neurodegenerative diseases

Pleiotropic effects of MIF on Alzheimer’s disease

The multifaced role of MIF on Parkinson’s disease

Concluding remarks

Footnotes

Funding

Acknowledgements

Declaration of conflicting interests

ORCID iDs

References